Join
Live feed
·
PRReleasevia Quantisnow
Aadi Bioscience Inc. logo

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

ByQuantisnow·Wall Street's wire, on your screen.
AADI· Aadi Bioscience Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AADI (Aadi Bioscience Inc.) and more on Quantisnow.